The Insulin Resistance Intervention after Stroke trial: A perspective on future practice and research
The Insulin Resistance Intervention after Stroke trial: A perspective on future practice and research
复制标题
DOI：
10.1177/1747493016660099
复制
发表时间：
2016-10-01
影响因子：
6.7
通讯作者：
Sprigg, Nikola
中科院分区：
文献类型：
--
作者：
Bath, Philip M.;Appleton, Jason P.;Sprigg, Nikola
缺血性中风和短暂性脑缺血发作后复发事件的预防已得到公认，并基于生活方式的改变、抗血栓药物、他汀类药物、抗高血压药物和颈动脉手术。国际IRIS试验评估了吡格列酮（一种降糖胰岛素增敏药物）是否会减少缺血性卒中或短暂性脑缺血发作患者的复发性血管事件。4.8年后，吡格列酮治疗与血管事件和新发糖尿病减少，体重增加，水肿和骨折相关。吡格列酮可作为预防卒中或短暂性脑缺血发作患者进一步事件的补充策略。
The prevention of recurrent events after ischaemic stroke and transient ischaemic attack is well established and based on lifestyle changes, antithrombotics, statins, antihypertensives and carotid surgery. The international IRIS trial assessed whether pioglitazone, a glucose-lowering insulin-sensitizing drug, would reduce recurrent vascular events in patients with ischaemic stroke or transient ischaemic attack. After 4.8 years, pioglitazone therapy was associated with reduced vascular events and new diabetes, and an increase in weight, oedema and bone fractures. Pioglitazone may add to the strategies for preventing further events in patients with stroke or transient ischaemic attack.